The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Basel: Roche has announced that the US Food and Drug Administration (FDA) has approved Gazyva/Gazyvaro (obinutuzumab) for the ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...

FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data –– Gazyva is the only anti-CD20 monoclonal antibody to demonstrate a ...

The anti-CD20 antibody, developed by Roche’s Genentech along with Biogen and already approved for multiple oncology indications, is branching into autoimmune disease. Its B cell–targeting mechanism of ...

Roche’s Gazyva/Gazyvaro receives US FDA approval for the treatment of lupus nephritis: Basel Wednesday, October 22, 2025, 10:00 Hrs [IST] Roche announced that the US Food and Dr ...

Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis is a debilitating condition that ...

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data1,2Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody t ...

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro's superiority over standard therapy alone1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to ...

The donation came from the David Koch Jr. Foundation to enable researchers at Stanford to redefine treatment for pediatric ...

The Lupus Foundation of America (LFA) celebrated exceptional lupus researchers at the 20th Anniversary Evelyn V. Hess Reception. Karen Costenbader, MD, MPH, Brigham and Women's Hospital, was honored ...